These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 10655511)

  • 1. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
    Rekasi Z; Varga JL; Schally AV; Halmos G; Groot K; Czompoly T
    Proc Natl Acad Sci U S A; 2000 Feb; 97(3):1218-23. PubMed ID: 10655511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
    Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
    Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro.
    Csernus V; Schally AV; Groot K
    Peptides; 1999; 20(7):843-50. PubMed ID: 10477085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
    Plonowski A; Varga JL; Schally AV; Krupa M; Groot K; Halmos G
    Int J Cancer; 2002 Apr; 98(4):624-9. PubMed ID: 11920625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.
    Collado B; Carmena MJ; Sánchez-Chapado M; Ruíz-Villaespesa A; Bajo AM; Fernández-Martínez AB; Varga JL; Schally AV; Prieto JC
    Int J Oncol; 2005 Jun; 26(6):1629-35. PubMed ID: 15870879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of antagonistic analogs of GHRH on GH3 pituitary cells overexpressing the human GHRH receptor.
    Kovacs M; Schally AV; Lee EJ; Busto R; Armatis P; Groot K; Varga JL
    J Endocrinol; 2002 Nov; 175(2):425-34. PubMed ID: 12429040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
    Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors.
    Cunha SR; Mayo KE
    Endocrinology; 2002 Dec; 143(12):4570-82. PubMed ID: 12446584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) on hormone secretion from sheep pituitary cells in vitro.
    Sawangjaroen K; Anderson ST; Curlewis JD
    J Neuroendocrinol; 1997 Apr; 9(4):279-86. PubMed ID: 9147291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intestinal polypeptide (VIP) phase-shifts the rat suprachiasmatic nucleus clock in vitro.
    Reed HE; Meyer-Spasche A; Cutler DJ; Coen CW; Piggins HD
    Eur J Neurosci; 2001 Feb; 13(4):839-43. PubMed ID: 11207820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of GHRH and peptides from the vasoactive intestinal peptide family on cAMP production of human cancer cell lines in vitro.
    Csernus V; Schally AV; Groot K
    J Endocrinol; 1999 Nov; 163(2):269-80. PubMed ID: 10556777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
    Juarranz MG; De Neef P; Robberecht P
    Prostate; 1999 Sep; 41(1):1-6. PubMed ID: 10440869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation.
    Garcia-Fernandez MO; Schally AV; Varga JL; Groot K; Busto R
    Breast Cancer Res Treat; 2003 Jan; 77(1):15-26. PubMed ID: 12602901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone-releasing hormone is produced by rat Leydig cell in culture and acts as a positive regulator of Leydig cell function.
    Ciampani T; Fabbri A; Isidori A; Dufau ML
    Endocrinology; 1992 Dec; 131(6):2785-92. PubMed ID: 1332849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs.
    Kiaris H; Schally AV; Busto R; Halmos G; Artavanis-Tsakonas S; Varga JL
    Proc Natl Acad Sci U S A; 2002 Jan; 99(1):196-200. PubMed ID: 11773624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors.
    Igarashi H; Ito T; Pradhan TK; Mantey SA; Hou W; Coy DH; Jensen RT
    J Pharmacol Exp Ther; 2002 Nov; 303(2):445-60. PubMed ID: 12388623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.
    Varga JL; Schally AV; Csernus VJ; Zarándi M; Halmos G; Groot K; Rékási Z
    Proc Natl Acad Sci U S A; 1999 Jan; 96(2):692-7. PubMed ID: 9892695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
    Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
    Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interactive effects of VIP, PHI, GHRH, and SRIF on the release of growth hormone from cultured adenohypophysial cells in cattle.
    Soliman EB; Hashizume T; Ohashi S; Kanematsu S
    Endocr J; 1995 Oct; 42(5):717-22. PubMed ID: 8574298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity.
    Ito T; Igarashi H; Pradhan TK; Hou W; Mantey SA; Taylor JE; Murphy WA; Coy DH; Jensen RT
    Peptides; 2001 Jul; 22(7):1139-51. PubMed ID: 11445245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.